Author:
von Hardenberg Jost,Ritter Manuel,Wenz Frederik,Abaci Ali
Publisher
Springer Berlin Heidelberg
Reference60 articles.
1. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Briganti A (2014). Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol, 65(3):554–562. doi: 10.1016/j.eururo.2013.09.025
2. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (2014) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Prostatakarzinoms, Langversion 3.1. AWMF-Registernummer: 034/022OL. 2014
3. Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M, Palmer S, Matsugasumi T, Marien A, Bernhard JC, Rewcastle JC, Eggesbø HB, Gill IS (2014) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794
4. Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Bolla M (2006) Guidelines for primary radiotherapy of patients with prostate cancer. Radiotherapy and Oncology 79(3):259–269. doi: 10.1016/j.radonc.2006.05.012
5. Bolla M, De Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Collette L (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527. doi: 10.1056/NEJMoa0810095